Genomics stocks closed sharply lower on Wednesday as the biotech sector tumbled for a second day due to profit-taking following the long holiday weekend, analysts said.

Celera Genomics (NYSE: CRA) closed at 100 7/16, down 4 1/16, or 3.9 percent, following a 7 percent drop on Tuesday. Incyte Genomics (Nasdaq: INCY) ended the session down 2 1/16, or 5.4 percent, at 36 1/2 following a 4.2 percent decline the previous day. And Affymetrix (Nasdaq: AFFX) shed 4 15/16, or 6.6 percent, to close at 70 on the heels of a 5.1 percent decline on Tuesday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.